Yuhan Corporation (KRX:000100)

South Korea · Delayed Price · Currency is KRW

75,900

-1,600 (-2.06%)

At close: Sep 18, 2026

Market Cap	5.66T -34.9%
Revenue (ttm)	2.28T +5.4%
Net Income	234.09B +195.3%
EPS	3,139.61 +193.3%
Shares Out	74.76M
PE Ratio	24.17
Forward PE	48.01
Dividend	600.00 (0.79%)
Ex-Dividend Date	Feb 26, 2026

Volume	514,417
Open	78,000
Previous Close	77,500
Day's Range	75,900 - 78,300
52-Week Range	65,000 - 129,200
Beta	0.42
Analysts	Buy
Price Target	114,529.41 (+50.9%)
Earnings Date	Nov 13, 2026

About Yuhan

Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperl... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1926

Employees 2,082

Stock Exchange Korea Stock Exchange

Ticker Symbol 000100

Full Company Profile

Financial Performance

In 2025, Yuhan's revenue was 2.19 trillion, an increase of 5.75% compared to the previous year's 2.07 trillion. Earnings were 191.09 billion, an increase of 170.33%.

Financial Statements

Analyst Summary

According to 17 analysts, the average rating for 000100 stock is "Buy." The 12-month stock price target is ₩114,529, which is an increase of 50.90% from the latest price.

Price Target

₩114,529

(50.90% upside)

Analyst Consensus: Buy

Stock Forecasts